Loading News...
Volver al Panel

Regeneron Pharmaceuticals, Inc. (REGN)

Valores intradiarios en tiempo real

Resumen del Mercado

From:
To:
REGN Intraday
No data available
SímboloREGN
Fecha de SalidaApr 2, 1991
CEODr. Leonard S. Schleifer M.D., Ph.D.
Empleados a Tiempo Completo15.4k
SectorHealthcare
IndustriaBiotechnology
PaísUnited States
BolsaNasdaqGS
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Rendimiento
PeríodoRentabilidad %Cambio de Valor
1 Día
-0.23%
-2.12 US$
5 Días
-3.58%
-34.25 US$
1 Mes
+14.34%
+115.55 US$
6 Meses
+44.19%
+282.34 US$

Analizando el Mercado con IA

Evaluando los últimos 30 días de historial y métricas fundamentales de REGN...

Estadísticas Clave
Cap. de Mercado
95.24B
Relación P/E
20.35
Rend. de Div.
0.41%
Máx. 52 Semanas
$991.73
Mín. 52 Semanas
$591.52

Consenso de Analistas

CONSENSOCompra
ALCISTA1967.9%
NEUTRAL932.1%
BAJISTA00.0%

Objetivos de Precios de Analistas a 52 Semanas

Objetivo Mín.
$812.00
Objetivo Máx.
$1175.00
Actual$921.22
Objetivo Prom.$991.00

Recomendaciones de Analistas

Precio Objetivo:$991.00($812.00 - $1175.00)
FirmaCalificaciónPrecio ObjetivoPotencial de AlzaFecha
Leerink PartnersMarket Perform$997.00+8.23%2/11/2026
BernsteinMarket Perform$812.00-11.86%2/11/2026
Morgan StanleyEqual-Weight$855.00-7.19%2/11/2026
Truist SecuritiesBuy$982.00+6.60%2/11/2026
RBC CapitalSector Perform$913.00-0.89%2/11/2026
GuggenheimBuy$1100.00+19.41%2/11/2026
Wells FargoEqual-Weight$925.00+0.41%2/11/2026
Evercore ISI GroupOutperform$1075.00+16.69%2/11/2026
Canaccord GenuityBuy$1175.00+27.55%2/11/2026
Cantor FitzgeraldOverweight$980.00+6.38%2/11/2026

¿Buscas más valores? Explóralos en el screener

Pensamientos de la Comunidad

Comparta su análisis y sentimiento sobre REGN

Únase a la comunidad para compartir su análisis